Transforming activity of a novel mutant of HPV16 E6E7 fusion gene

Virologica Sinica

Volumn 26, Issue 3, 2011, Pages 206-213

  Xie, Qiang ^a   Zhou, Zhi Xiang ^a   Li, Ze Lin ^a   Zeng, Yi ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

E6; E7; Gene mutation; Gene optimization; Human papillomavirus (HPV); Transformation

Indexed keywords

E6E7 FUSION PROTEIN; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HYBRID PROTEIN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; CARCINOGENICITY; CELL STRAIN 3T3; CODON USAGE; CONTROLLED STUDY; E6E7 FUSION GENE; EXPRESSION VECTOR; GENE CONSTRUCT; GENE SEQUENCE; GENETIC TRANSFECTION; GENETIC TRANSFORMATION; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; SEVERE COMBINED IMMUNODEFICIENCY; SITE DIRECTED MUTAGENESIS; VIRUS GENE; ANIMAL; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; MUTATION; PAPILLOMAVIRUS INFECTION; PHYSIOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION;

HUMAN PAPILLOMAVIRUS; MAMMALIA; MUS;

ANIMALS; CELL TRANSFORMATION, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, SCID; MUTATION; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS;

EID: 80053098658     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-011-3178-9     Document Type: Article

References (12)

1. Bafna S, Singh A P, Moniaux N, et al. 2008. MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res, 68 (22): 9231-9238.
2. Bequet-Romero M, Lopez-Ocejo O. 2000. Angio-genesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem Biophys Res Commun, 277 (1):55-61.
3. Edmonds C, Vousden K H. 1989. A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol, 63 (6): 2650-2656. (Pubitemid 19137543)
4. Hung C F, Monie A, Weng W H, et al. 2010. DNA vaccines for cervical cancer. Am J Transl Res, 2 (1): 75-87.
5. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, et al. 2000. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene, 19: 4611-4620.
6. Nadagawa S, Watanabe S, Yoshikawa H, et al. 1995. Mutational Analysis of Human Papillomavirus Type 16 E6 Protein: Transforming Function for Human Cells and Degradation of p53 in vitro. Virology, 212 (2): 535-542.
7. Ohlschläger P, Quetting M, Alvarez G, et al. 2009. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequenceoptimized genetic adjuvants. Int J Cancer, 125 (1): 189-198.
8. Toussaint-Smith E, Donner D B, Roman A. 2004. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene, 23:2988-2995. (Pubitemid 38648189)
9. Walboomers J M, Jacobs M V, Manos M M, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189: 12-19. (Pubitemid 29406813)
10. Watanabe S, Kanda T, Sato H, et al. 1990. Mutational analysis of human papillomavirus type 16 E7 functions. J Virol, 64 (1): 207-214. (Pubitemid 20032618)
11. Yan J, Reichenbach D K, Corbitt N, et al. 2009. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine, 27 (3): 431-440.
12. Zhou X S, Qian X L, Zhao Q Z, et al. 2004. Efficient expression of modified human papillomavirus 16 E6/E7 fusion protein and the antitumor efficacy in a mouse model. Biol Pharm Bull. 27 (3): 303-307.